Back to search results

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Abroad (travel likely)RecruitingPHASE3

Conditions

Generalized Myasthenia Gravis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Neuromuscular Research Center, Phoenix, Arizona, United States

    Contact: Study coordinator (Lucia Rodriguez) · nrsresearch@nrcaz.com
    Contact: Principal Investigator (Kumaraswamy Sivakumar)

  • Honor Health Research Institute, Scottsdale, Arizona, United States

    Contact: Study coordinator (Kristy Osgood) · kosgood@honorhealth.com · 480-323-3990
    Contact: Principal Investigator (Anne Hatch)

  • Fullerton Neuro and Headache Ctr, Fullerton, California, United States

    Contact: Study coordinator (Alexandra Vasquez) · avasquez@fullertonneuro.net · 714-738-0800
    Contact: Principal Investigator (Jack H Florin)

  • University Of Southern California, Los Angeles, California, United States

    Contact: Study coordinator (Nasrin Ahmed) · nahmed@advmedresearch.com · 323-865-3900
    Contact: Principal Investigator (Said R Beydoun.)

  • Univ Cali Irvine ALS Neuromuscular, Orange, California, United States

    Contact: Study coordinator (Karina Bjazevic) · kbjazevi@hs.uci.edu · 714-456-2332
    Contact: Principal Investigator (Ali Habib)

  • California Pacific Medical Center, Sacramento, California, United States

    Contact: Study coordinator (Daniela Sanchez) · daniela.sanchez@sutterhealth.org · 415-600-3604
    Contact: Principal Investigator (Liberty Jenkins)

  • Medstar Washington Hospital Center, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Anu Bhooshan) · anu.r.bhooshan@medstar.net
    Contact: Principal Investigator (Nicholas Streicher)

  • SFM Clinical Research LLC, Boca Raton, Florida, United States

    Contact: Study coordinator (Gabrielle Demaria) · Gabrielle@sfmresearch.com · 561-939-0300
    Contact: Principal Investigator (Marc Feinberg)

  • Homestead Assoc In Research Inc, Homestead, Florida, United States

    Contact: Study coordinator (Daydene Ordaz) · dordaz@associatesinresearch.com · 305-246-0873
    Contact: Principal Investigator (Christopher Jimenez)

  • Neurology Associates PA, Maitland, Florida, United States

    Contact: Study coordinator (Kelly Holley) · admin@naparesearch.com · 407-647-5996
    Contact: Principal Investigator (Arnaldo Isa)

  • AdventHealth, Orlando, Florida, United States

    Contact: Study coordinator (Samuel Pierre Louis) · samuel.pierrelouis@adventhealth.com · +1 407 303 6729
    Contact: Principal Investigator (Anita Fletcher)

  • Neurological Services of Orlando PA, Orlando, Florida, United States

    Contact: Study coordinator (Tanya Palafox) · tanya.nso@outlook.com · 941-400-4578
    Contact: Principal Investigator (Daniel H Jacobs)

  • University of Chicago Medical Centr, Chicago, Illinois, United States

    Contact: Study coordinator (Deekshitha Turaka) · deekshitha.turaka@bsd.uchicago.edu
    Contact: Principal Investigator (Kourosh Rezania)

  • Mid Atlantic Epilepsy and Sleep Ctr, Bethesda, Maryland, United States

    Contact: Study coordinator (Arkady Barber) · barbera@epilepsydc.com
    Contact: Principal Investigator (Jonathan Ross)

  • Neuromuscular Diagnostic Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Isaac McCarthy) · imccarthy2@mgh.harvard.edu · 617-726-8736
    Contact: Principal Investigator (Amanda Guidon)

  • Michigan State University-Department of Neurology, East Lansing, Michigan, United States

    Contact: Study coordinator (Aubrey Alexander) · alexaub@msu.edu
    Contact: Principal Investigator (Amit Sachdev)

  • Dent Neurological Institute, Buffalo, New York, United States

    Contact: Study coordinator (Anna Mattle) · amattle@dentinstitute.com · 716-887-4799
    Contact: Principal Investigator (Bennett Myers)

  • Univ of Cincinnati Medical Center, Cincinnati, Ohio, United States

    Contact: Study coordinator (Kaiya Payne) · payne2ka@ucmail.uc.edu · 513-475-8730
    Contact: Principal Investigator (Hani Kushlaf)

  • Cleveland Clinic Foundation, Cleveland, Ohio, United States

    Contact: Study coordinator (Debbie Hastings) · hastind@ccf.org
    Contact: Principal Investigator (Yuebing Li)

  • University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

    Contact: Study coordinator (Gabriela Niizawa) · niizawaga@upmc.edu · 412-692-4920
    Contact: Principal Investigator (Fang Sun)

  • Houston Methodist Hospital, Houston, Texas, United States

    Contact: Study coordinator (Delrose Vernon) · davernon@houstonmethodist.org · 713-441-9484
    Contact: Principal Investigator (Ericka Greene)

  • UT Health Science Center, Houston, Texas, United States

    Contact: Study coordinator (Ari Broussard) · ari.broussard@uth.tmc.edu
    Contact: Principal Investigator (Thy Nguyen)

  • University of WA Division of Cardio, Seattle, Washington, United States

    Contact: Study coordinator (Kaycie Opiyo) · tkaycie@uw.edu · 206-685-1048
    Contact: Principal Investigator (Barbara Jane Distad)

  • Center for Neurological Disorders G, Greenfield, Wisconsin, United States

    Contact: Study coordinator (Emily Barraza) · Emily.barraza@cndmilwaukee.com
    Contact: Principal Investigator (Bhupendra Khatri.)

  • Novartis Investigative Site, Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site, Caba, Argentina

  • Novartis Investigative Site, Capital Federal, Argentina

  • Novartis Investigative Site, San Miguel de Tucumán, Argentina

  • Novartis Investigative Site, Kogarah, New South Wales, Australia

  • Novartis Investigative Site, Fitzroy, Victoria, Australia

  • Novartis Investigative Site, Southport, Australia

  • Novartis Investigative Site, Leuven, Vlaams Brabant, Belgium

  • Novartis Investigative Site, Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site, Brasília, Federal District, Brazil

  • Novartis Investigative Site, Caxias do Sul, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, São Paulo, Brazil

  • Novartis Investigative Site, Edmonton, Alberta, Canada

  • Novartis Investigative Site, London, Ontario, Canada

  • Novartis Investigative Site, Ottawa, Ontario, Canada

  • Novartis Investigative Site, Québec, Quebec, Canada

  • Novartis Investigative Site, Hefei, Anhui, China

  • Novartis Investigative Site, Guangzhou, Guangdong, China

  • Novartis Investigative Site, Shijiazhuang, Hebei, China

  • Novartis Investigative Site, Zhengzhou, Henan, China

  • Novartis Investigative Site, Wuhan, Hubei, China

  • Novartis Investigative Site, Wuxi, Jiangsu, China

  • Novartis Investigative Site, Changchun, Jilin, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Qingdao, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Bordeaux, France

  • Novartis Investigative Site, Nice, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Strasbourg, France

  • Novartis Investigative Site, Toulouse, France

  • Novartis Investigative Site, Kutaisi, Georgia

  • Novartis Investigative Site, Tbilisi, Georgia

  • Novartis Investigative Site, Tbilisi, Georgia

  • Novartis Investigative Site, Frankfurt am Main, Hesse, Germany

  • Novartis Investigative Site, Gummersbach, Germany

  • Novartis Investigative Site, Hamburg, Germany

  • Novartis Investigative Site, Münster, Germany

  • Novartis Investigative Site, Gurugram, Haryana, India

  • Novartis Investigative Site, Mangalore, Karnataka, India

  • Novartis Investigative Site, Nashik, Maharashtra, India

  • Novartis Investigative Site, New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site, Ludhiana, Punjab, India

  • Novartis Investigative Site, Vellore, Tamil Nadu, India

  • Novartis Investigative Site, Hyderabad, Telangana, India

  • Novartis Investigative Site, Lucknow, Uttar Pradesh, India

  • Novartis Investigative Site, Bergamo, BG, Italy

  • Novartis Investigative Site, Orbassano, TO, Italy

  • Novartis Investigative Site, Naples, Italy

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Nishinomiya, Hyōgo, Japan

  • Novartis Investigative Site, Hanamaki, Iwate, Japan

  • Novartis Investigative Site, Sendai, Miyagi, Japan

  • Novartis Investigative Site, Suita, Osaka, Japan

  • Novartis Investigative Site, Higashi-Matsuyama, Saitama, Japan

  • Novartis Investigative Site, Koshigaya, Saitama, Japan

  • Novartis Investigative Site, Shinjuku Ku, Tokyo, Japan

  • Novartis Investigative Site, Chiba, Japan

  • Novartis Investigative Site, Fukuoka, Japan

  • Novartis Investigative Site, Fukushima, Japan

  • Novartis Investigative Site, Hiroshima, Japan

  • Novartis Investigative Site, Lublin, Lublin Voivodeship, Poland

  • Novartis Investigative Site, Lublin, Lublin Voivodeship, Poland

  • Novartis Investigative Site, Krakow, POL, Poland

  • Novartis Investigative Site, Bydgoszcz, Woj Kujawsko Pomorskie, Poland

  • Novartis Investigative Site, Bydgoszcz, Poland

  • Novartis Investigative Site, Katowice, Poland

  • Novartis Investigative Site, Lodz, Poland

  • Novartis Investigative Site, Lublin, Poland

  • Novartis Investigative Site, Lublin, Poland

  • Novartis Investigative Site, Poznan, Poland

  • Novartis Investigative Site, Rzeszów, Poland

  • Novartis Investigative Site, Skorzewo, Poland

  • Novartis Investigative Site, Szczecin, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Brasov, Romania

  • Novartis Investigative Site, Bucharest, Romania

  • Novartis Investigative Site, Sibiu, Romania

  • Novartis Investigative Site, Belgrade, Serbia

  • Novartis Investigative Site, Niš, Serbia

  • Novartis Investigative Site, Novi Sad, Serbia

  • Novartis Investigative Site, Busan, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Santiago Compostela, A Coruna, Spain

  • Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Lleida, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Málaga, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Kaohsiung City, Taiwan

  • Novartis Investigative Site, Tainan, Taiwan

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Taoyuan, Taiwan

  • Novartis Investigative Site, London, United Kingdom

View source on ClinicalTrials.gov(opens in a new tab)